
-
Evofem Biosciences OTC MARKETS:EVFM Evofem Biosciences, Inc., is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, 'EVOGUARD,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women.
Location: 12400 High Bluff Dr Ste 600, California, 92130-3077, US | Website: www.evofem.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
50.26M
Cash
202K
Avg Qtr Burn
-411.8K
Short % of Float
0.07%
Insider Ownership
0.00%
Institutional Own.
0.10%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phexxi™ Details Birth control | Approved Quarterly sales | |
EVO100 Details Sexually transmitted infections | Failed Discontinued | |
Phexxi™ Details Birth control, Urinary tract infection | Failed Discontinued |